Welcome to our dedicated page for Generate Biomedicines SEC filings (Ticker: GENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Generate Biomedicines's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Generate Biomedicines's regulatory disclosures and financial reporting.
Generate Biomedicines Chief Technology Officer Gevorg Grigoryan reported two grants of stock options to acquire company shares. One option covers 295,608 shares and vests in two equal installments on February 19, 2029 and February 19, 2030, subject to continued service. A second option covers 196,368 shares and vests in forty-eight equal monthly installments following February 19, 2026, also conditioned on his continued service. Both awards are recorded at an exercise price of $0.00 per share, reflecting their nature as compensatory grants rather than open-market purchases.
Generate Biomedicines, Inc. director and CEO Michael Nally reported several insider equity transactions. An entity associated with him, the MTN 2024 GST Trust, converted 1,000,000 shares of Series A Preferred Stock into 658,327 shares of Common Stock at no per-share price upon the company’s initial public offering on March 2, 2026, and he disclaims beneficial ownership of those trust-held shares except for any pecuniary interest.
Separately, Nally received two direct stock option awards, each covering 844,595 shares, on February 26, 2026, as grants at a stated exercise price of $0.00 per share. One option vests in two equal installments on February 19, 2029 and February 19, 2030, and the other vests in 48 equal monthly installments after February 19, 2026, in each case subject to his continued service. As of February 26, 2026, he held 552,707 shares of Common Stock directly and 999,793 shares indirectly through the MTN 2024 GRAT.
Generate Biomedicines director Jane L. Mendillo reported two transactions involving the company’s securities. On March 2, 2026, she made an open-market purchase of 1,500 shares of Common Stock at $16.00 per share, bringing her directly held common shares to 1,500.
On February 26, 2026, she also received a grant of 29,561 stock options with an exercise price of $0.00. According to the disclosure, the shares underlying this option vest in full on February 19, 2027, subject to her continued service with the company on that vesting date.
Fanucci Marsha reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines, Inc. director Marsha Fanucci reported receiving a stock option grant for 29,561 shares on February 26, 2026. The option has a price per share of $0.00, reflecting a compensatory award rather than an open-market purchase. These option shares vest in full on February 19, 2027, if she continues in service through that date.
Generate Biomedicines, Inc. director Parker Paul Gray received a grant of stock options covering 29,561 shares on February 26, 2026. The options were awarded at an exercise price of $0.00 per share as part of his compensation.
The option grant will vest in full on February 19, 2027, as long as Gray continues to serve the company through that vesting date. After this grant, he holds derivative securities representing 29,561 shares directly.
Generate Biomedicines, Inc. reported multiple insider-related transactions involving funds affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by these funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering. On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each bought 1,562,500 shares of common stock at $16 per share in open-market or private transactions, for a total of 4,687,500 shares purchased. Separately, on February 26, 2026, Noubar Afeyan received a grant of 29,561 stock options that vest in full on February 19, 2027, subject to continued service.
Generate Biomedicines, Inc. has overhauled its corporate charter and bylaws in connection with completing its initial public offering. The company filed an amended and restated certificate of incorporation in Delaware that authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock and removes references to prior preferred series.
The new charter also removes stockholders’ ability to act by written consent or to call special meetings, centralizing these corporate actions in formal meeting processes. Updated bylaws establish detailed procedures for stockholder meetings, add advance notice requirements for proposals and director nominations, and align with the revised charter provisions.